High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
复制标题
治疗后血清中可溶性程序性细胞死亡配体 1 的高水平可预测结外 NK/T 细胞淋巴瘤患者的早期复发和不良预后。
DOI：
10.18632/oncotarget.8847
复制
发表时间：
2016-05-31
期刊：
影响因子：
--
通讯作者：
Lu Y
中科院分区：
文献类型：
--
作者：
Wang H;Wang L;Liu WJ;Xia ZJ;Huang HQ;Jiang WQ;Li ZM;Lu Y
The impact of serum levels of soluble programmed cell death ligand 1 (sPD-L1) on prognosis in patients with Epstein-Barr virus-associated malignancies has never been investigated. We prospectively measured pre- and post-treatment serum sPD-L1 levels and evaluated their prognostic value in 97 patients with newly diagnosed, early stage extranodal NK/T-cell lymphoma (ENKTCL) treated with asparaginase-based chemotherapy followed by radiotherapy. For predicting survival outcomes, serum sPD-L1 levels of 3.23 ng/mL and 1.12 ng/mL were respectively identified for pre- and post-treatment cut-off levels. Patients with high pretreatment (>3.23 ng/mL) had shorter progression-free survival (PFS) and overall survival (OS). In a multivariate survival analysis, post-treatment sPD-L1 >1.12 ng/mL, treatment response (complete vs. non-complete response), and stage II disease were independent prognostic factors for shorter PFS and OS. In patients with a complete response, post-treatment sPD-L1 >1.12 ng/mL was associated with shorter PFS and OS. In patients with high pretreatment sPD-L1 levels (>3.23 ng/mL), low post-treatment sPD-L1 level (≤1.12 ng/mL) correlated with longer PFS and OS. Our data suggest the post-treatment sPD-L1 level is a potent biomarker for predicting early relapse and poor prognosis in early stage ENKTCL patients treated with asparaginase, and may be a useful marker of minimal residual disease.
登录
查看更多内容
影响因子：
0.6
作者：
Lim, Megan S;de Leval, Laurence;Quintanilla-Martinez, Leticia
通讯作者：
Quintanilla-Martinez, Leticia
影响因子：
11.5
作者：
Konishi, J;Yamazaki, K;Nishimura, M
通讯作者：
Nishimura, M
DOI：
10.1158/1078-0432.ccr-13-0855
发表时间：
2013-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Chen BJ;Chapuy B;Ouyang J;Sun HH;Roemer MG;Xu ML;Yu H;Fletcher CD;Freeman GJ;Shipp MA;Rodig SJ
通讯作者：
Rodig SJ
PD-L1 高表达与 870 名中国乳腺癌患者预后不良相关
影响因子：
--
作者：
Qin T;Zeng YD;Qin G;Xu F;Lu JB;Fang WF;Xue C;Zhan JH;Zhang XK;Zheng QF;Peng RJ;Yuan ZY;Zhang L;Wang SS
通讯作者：
Wang SS
影响因子：
12.8
作者：
Wang, Biyun;Li, Xiao-Qiu;Guo, Ye
通讯作者：
Guo, Ye